GlobeNewswire: IntelGenx Corp. Contains the last 10 of 355 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T06:59:31ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/14/2846720/0/en/IntelGenx-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-21-2024-Conference-Call-to-Follow.html?f=22&fvtc=4&fvtv=13304IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow2024-03-14T20:30:00Z<![CDATA[SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024.]]>https://www.globenewswire.com/news-release/2024/03/11/2843679/0/en/IntelGenx-Enters-Into-a-Third-Amended-and-Restated-Loan-Agreement-With-atai-Life-Sciences.html?f=22&fvtc=4&fvtv=13304IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences2024-03-11T11:45:00Z<![CDATA[SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx Corp.”), has entered into a third amended and restated loan agreement dated as of March 8, 2024 (amending the second amended and restated loan agreement dated as of September 30, 2023) (the “Loan Agreement”) with atai Life Sciences AG (“atai”), pursuant to which, among other things, atai has agreed to make (i) one (1) additional term loan in the amount of US$1,000,000 to IntelGenx Corp., which loan is to be disbursed within three (3) business days of the execution of the Loan Agreement (the “First Tranche Loan”), and (ii) one (1) additional term loan in the amount of US$1,000,000 to IntelGenx Corp., which loan is to be disbursed upon the achievement of a pre-defined milestone (the “Second Tranche Loan” and collectively with the Second Tranche Loan, the “Additional Term Loans”). The Additional Term Loans will mature on February 1, 2026.]]>https://www.globenewswire.com/news-release/2024/02/20/2832062/0/en/UPDATE-IntelGenx-Launches-Preferred-Share-Regulation-A-Offering.html?f=22&fvtc=4&fvtv=13304UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering2024-02-20T15:50:57Z<![CDATA[SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A Preferred Stock”), par value $0.00001 per share, at an offering price of $10.00 per share (the “Offering”), for a maximum Offering amount of $20,000,000.]]>https://www.globenewswire.com/news-release/2024/02/20/2831737/0/en/IntelGenx-Launches-Preferred-Share-Regulation-A-Offering.html?f=22&fvtc=4&fvtv=13304IntelGenx Launches Preferred Share Regulation A Offering2024-02-20T12:50:15Z<![CDATA[SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A Preferred Stock”), par value $0.00001 per share, at an offering price of $10.00 per share (the “Offering”), for a maximum Offering amount of $20,000,000.]]>https://www.globenewswire.com/news-release/2024/02/05/2823485/0/en/Studies-Validate-Advantages-of-Administering-Drugs-to-Pets-via-IntelGenx-s-VetaFilm-Platform.html?f=22&fvtc=4&fvtv=13304Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform2024-02-05T13:00:00Z<![CDATA[SAINT LAURENT, Quebec, Feb. 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced positive results from a proof-of-concept (“POC”) study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm® platform in healthy dogs and cats. The POC study was conducted through a research collaboration with the University Prince Edward Island (“UPEI”), one of North America’s leading veterinary universities.]]>https://www.globenewswire.com/news-release/2023/12/18/2797713/0/en/IntelGenx-Announces-New-Animal-Health-Partnership-Enters-into-Development-and-License-Agreements-for-VetaFilm.html?f=22&fvtc=4&fvtv=13304IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®2023-12-18T12:15:00Z<![CDATA[SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license agreements (collectively the “Agreements”) with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC (“Covenant Animal Health”).]]>https://www.globenewswire.com/news-release/2023/12/05/2790856/0/en/IntelGenx-Announces-Closing-of-Previously-Announced-Subsequent-Non-Brokered-Private-Placement-With-atai-Life-Sciences-for-Aggregate-Gross-Proceeds-of-US-750-000.html?f=22&fvtc=4&fvtv=13304IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,0002023-12-05T13:00:00Z<![CDATA[SAINT LAURENT, Quebec, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the previously announced subsequent non-brokered private placement (the “Subsequent atai Subscription”) of 750 units (“US Units”) with atai Life Sciences AG (“atai”) for aggregate gross proceeds of US$750,000, on the same terms as the August 31, 2023, offering of units (the “Initial Offering” and together with the Subsequent atai Subscription, the “Offering”), following the Shareholder Approvals (as defined below) obtained at the special meeting held on November 28, 2023 (the “Special Meeting”).]]>https://www.globenewswire.com/news-release/2023/12/04/2789974/0/en/IntelGenx-Announces-Changes-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=13304IntelGenx Announces Changes to its Board of Directors2023-12-04T13:00:00Z<![CDATA[SAINT LAURENT, Quebec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors of the Company (the “Board”) effective December 2, 2023.]]>https://www.globenewswire.com/news-release/2023/11/28/2787357/0/en/IntelGenx-Announces-Shareholder-Approval-of-Financing-Transactions.html?f=22&fvtc=4&fvtv=13304IntelGenx Announces Shareholder Approval of Financing Transactions2023-11-28T21:05:00Z<![CDATA[SAINT LAURENT, Quebec, Nov. 28, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) is pleased to announce that, at its meeting held earlier today (the “Special Meeting”), the shareholders (the “Shareholders”) voted to approve all proposals related to financing transactions involving atai Life Sciences AG (“atai”) previously disclosed by the Company on August 31, 2023 (the “Financing Transactions”).]]>https://www.globenewswire.com/news-release/2023/11/14/2779952/0/en/IntelGenx-Receives-Approval-to-Conduct-MONTPARK-Montelukast-VersaFilm-Phase-2-Clinical-Trial-in-Patients-with-Parkinson-s-Disease.html?f=22&fvtc=4&fvtv=13304IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease2023-11-14T12:30:00Z<![CDATA[Phase 2 MONTPARK trial expected to begin recruiting patients in Q1 2024 Phase 2 MONTPARK trial expected to begin recruiting patients in Q1 2024]]>